Ovid Therapeutics Inc. (OVID) Tops Q2 EPS by 10c

Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q2 EPS of ($0.06), $0.10 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $67.8 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform